Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 23;10(9):1674-1688.
doi: 10.1021/acscentsci.4c00997. eCollection 2024 Sep 25.

C-H Labeling with [18F]Fluoride: An Emerging Methodology in Radiochemistry

Affiliations
Review

C-H Labeling with [18F]Fluoride: An Emerging Methodology in Radiochemistry

Jay S Wright et al. ACS Cent Sci. .

Abstract

Fluorine-18 is the most routinely employed radioisotope for positron emission tomography, a dynamic nuclear imaging modality. The radiolabeling of C-H bonds is an attractive method for installing fluorine-18 into organic molecules since it can preclude the cumbersome prefunctionalization of requisite precursors. Although electrophilic "F+" reagents (e.g., [18F]F2) are effective for C-H radiolabeling, state-of-the-art methodologies predominantly leverage high molar activity nucleophilic [18F]fluoride sources (e.g., [18F]KF) with substantial (pre)clinical advantages. Reflecting this, multiple nucleophilic C-H radiolabeling techniques of high utility have been disclosed over the past decade. However, the adoption of (pre)clinical C-H radiolabeling has been slow, and PET imaging agents are still routinely prepared via methods that, despite a high level of practicality, are limited in scope (e.g., SNAr, SN2 radiofluorinations). By addressing the drawbacks inherent to these strategies, C-H radiofluorination and radiofluoroalkylation carry the potential to complement and supersede state-of-the-art labeling methods, facilitating the expedited production of PET agents used in disease staging and drug development. In this Outlook, we showcase recent C-H labeling developments with fluorine-18 and discuss the merits, potential, and barriers to adoption in (pre)clinical settings. In addition, we highlight trends, challenges, and directions in this emerging field of study.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Utility of [11C]PiB positron emission tomography in human clinical trials toward the development of Alzheimer’s therapeutics.
Scheme 1
Scheme 1. Electrophilic C–H Radiofluorination. 1-18F
Scheme 2
Scheme 2. Mechanism of Decatungstate-Mediated Electrophilic C–H Radiofluorination
Scheme 3
Scheme 3. Direct sp2 C–H Fluorine-18 Labeling Reactions
Scheme 4
Scheme 4. Direct sp2 C–H Electrochemical Radiofluorination
Scheme 5
Scheme 5. Photochemical C–H Radiofluorination Mediated by 9, with Plausible Mechanism
O2 may induce rearomatization.
Scheme 6
Scheme 6. Photochemical C–H Radiofluoroalkylation Starting from 11, with Plausible Mechanism
Sulfinate byproduct may be produced.
Scheme 7
Scheme 7. Sequential C–H Radiofluorination Protocols
Scheme 8
Scheme 8. Multistep sp2 C–H Radiofluorination Methodologies
Scheme 9
Scheme 9. Directed Radiofluorination of sp3 C–H Bonds
Scheme 10
Scheme 10. Manganese-Mediated Radiofluorination of sp3 C–H Bonds
Scheme 11
Scheme 11. Directed Radiofluorination of sp3 C–H Bonds
Scheme 12
Scheme 12. Electrochemical sp3 C–H Radiofluorination

References

    1. Rinne J. O; Brooks D. J; Rossor M. N; Fox N. C; Bullock R.; Klunk W. E; Mathis C. A; Blennow K.; Barakos J.; Okello A. A; de LIano S. R. M.; Liu E.; Koller M.; Gregg K. M; Schenk D.; Black R.; Grundman M. 11C-PiB PET Assessment of Change in Fi Brillar Amyloid-β Load in Patients with Alzheimer’s Disease Treated with Bapineuzumab: A Phase 2, Double-Blind, Placebo-Controlled, Ascending-Dose Study. Lancet Neurol. 2010, 9, 363–372. 10.1016/S1474-4422(10)70043-0. - DOI - PubMed
    1. Anbar M.; Neta P. The Production and Use of F18-Labelled Organic Compounds. Int. J. Appl. Radiat. Isot. 1963, 14, 119–122. 10.1016/0020-708X(63)90105-4. - DOI - PubMed
    1. Scott P. J. H.; Hockley B. G.. Radiochemical Syntheses: Radiopharmaceuticals for Positron Emission Tomography; John Wiley & Sons, Ltd, 2012; Vol. 1,10.1002/9781118140345. - DOI
    1. Czernin J.; Allen-Auerbach M.; Nathanson D.; Herrmann K. PET/CT in Oncology: Current Status and Perspectives. Curr. Radiol. Rep. 2013, 1 (3), 177–190. 10.1007/s40134-013-0016-x. - DOI - PMC - PubMed
    1. Packard A. B. SNMMI Leadership Update: Advocating for Our Field. J. Nucl. Med. 2021, 62 (3), 15N. - PubMed

LinkOut - more resources